Haemonetics Corporation (HAE)

83,06 +0,33 (+0,40 %) À la clôture : 04:00PM EDT

Haemonetics Corporation

125 Summer Street
Boston, MA 02110
United States
781 848 7100
https://www.haemonetics.com

Secteur(s): Healthcare
Secteur d’activité: Medical Instruments & Supplies
Employés à temps plein: 3 657

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Christopher A. Simon	CEO, President & Director	3,6M	11,06M	1964
Mr. James C. D'Arecca CPA	CFO, Executive VP & Financial Officer	1,31M	S.O.	1971
Ms. Anila Lingamneni	Executive VP & CTO	1,08M	S.O.	1967
Ms. Michelle L. Basil	Executive VP, General Counsel & Secretary	1,24M	S.O.	1972
Mr. Josep Lluis Llorens	Executive Vice President of Global Manufacturing & Supply Chain	1,08M	162,13k	1962
Ms. Farris Maryanne Maunsell	VP, Chief Accounting Officer & Principal Accounting Officer	S.O.	S.O.	1976
Ms. Olga Guyette	Senior Director of Investor Relations	S.O.	S.O.	S.O.
Mr. Rajeev Varma	Senior Vice President of Strategy & Corporate Development	S.O.	S.O.	S.O.
Ms. Laurie A. Miller	Senior VP & Chief Human Resources Officer	S.O.	S.O.	1974
Dr. Jan Hartmann M.D.	Senior VP & Chief Medical Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2024 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Haemonetics Corporation en date du 1 juillet 2024 est 3. Les scores principaux sont Audit : 5; Société : 2; Droits des actionnaires : 4; Compensation : 6.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.